

Diabetic Retinopathy Guideline Committee Meeting 9

Date: 17th February 2023
Location: Virtual Meeting via Zoom
Minutes: Draft

Committee members present:	
Mike Burdon (Chair)	Present for all items
John Anderson	Present for all items
Amandeep Bedi	Present for all items
Philip Burgess	Present for all items
Rosalind Creer	Present for all items
Christiana Dinah	Present for items 1-4
Noemi Lois	Present for all items
Louis Savage	Present for all items
Diva Shah	Present for items 1-4
Lloyd Thomas	Present for all items
Bernadette Warren	Present for all items

In attendance:		
Astrid Aregui	Senior Medical Editor, NICE	Astrid Aregui
Keona Bennett	Administrator, Guideline Development Team	Present for all items
Becky Chadwick	Project Manager, Guideline Development Team	Present for items 1-4
Catrina Charlton	Guideline Commissioning Manager, NICE	Present for all items
Christine Harris	Project Manager, Guideline Development Team	Present for items 5-8
Kirsty Luckham	Technical Analyst (Health Economics)	Present for all items
Yolanda Martinez	Technical Analyst, Guideline Development Team	Present for all items
Syed Mohiuddin	Technical Adviser (Health Economics)	Present for all items
Philip Williams	Resource Impact Lead, NICE	Present for all items
Ahmed Yousef	Technical Analyst, Guideline Development Team	Present for all items

Apologies:	
John Anderson	Committee Member
Nicola Cunliffe	Project Manager, Guideline Development Team
Becky Wei Luo	Committee Member
Hannah Tebbs	Technical Analyst (Health Economics)

Magdalena Watras	Medicines Lead, NICE
------------------	----------------------

1. Welcome and DOIs for the meeting

The Chair welcomed the committee members and attendees to the 9th meeting on Diabetic Retinopathy. The committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received, these are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Diabetic Retinopathy. The Chair asked everyone to verbally declare any new interests that are not listed in the registry. No new interests were declared.

2. RQ9 - In people who are about to undergo or who have undergone cataract surgery, what is the effectiveness of treatments (before, during or after surgery) for managing:

- non-proliferative diabetic retinopathy
- proliferative diabetic retinopathy
- diabetic macular oedema

The Chair introduced Ahmed Yousef (AY) and Yolanda Martinez (YM), who presented RQ9 and led a discussion with the committee.

3. RQ 9 discussion cont.

The committee continued the discussion for RQ9.

4. HE presentation

The Chair introduced Kirsty Luckham (KL), who gave a presentation on health economics. The committee had the opportunity to engage and ask questions.

5. RQ1 What are the prognostic factors for the progression of non-proliferative diabetic retinopathy in people with diabetic retinopathy to?

- proliferative diabetic retinopathy
- diabetic macular oedema
- diabetic macular ischaemia

AY presented RQ1 and the committee had the opportunity to give feedback and ask questions.

6. RQ1 discussion cont.

The committee continued the discussion for RQ1.

6. RQ8 revisited - What are the clinical features or factors that suggest treatment should be switched or stopped for people diagnosed with proliferative diabetic retinopathy or diabetic macular oedema?

AY revisited RQ8 with the committee. They had the opportunity to give feedback and ask questions.

7. AOB, summary and next steps

The Chair confirmed the next meeting date, next steps and thanked those present for their contributions. The meeting concluded.